Protara Therapeutics (Protara Therapeutics) Debt-to-EBITDA : -0.11 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Protara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.00 Mil. Protara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $4.23 Mil. Protara Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-47.07 Mil. Protara Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Protara Therapeutics's Debt-to-EBITDA or its related term are showing as below:

TARA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.16 Med: -0.11 Max: -0.03
Current: -0.12

During the past 6 years, the highest Debt-to-EBITDA Ratio of Protara Therapeutics was -0.03. The lowest was -0.16. And the median was -0.11.

TARA's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs TARA: -0.12

Protara Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Protara Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics Debt-to-EBITDA Chart

Protara Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.03

-0.16

-0.10

-0.13

Protara Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.16	-0.12	-0.13	-0.13	-0.11

Competitive Comparison of Protara Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Protara Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protara Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Debt-to-EBITDA falls into.

Protara Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Protara Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.983	+	4.484)	/	-43.272
	=	-0.13

Protara Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1	+	4.227)	/	-47.072
	=	-0.11

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Protara Therapeutics (NAS:TARA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Protara Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Protara Therapeutics (Protara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

1KPA:Germany 1KPA:Germany

Address

345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010

Website

http://www.protaratx.com

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Executives

Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Jesse Shefferman	director, officer: CEO and President	C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry	officer: VP, Controller	345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari	officer: Chief Medical Officer	C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang	director	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo	officer: Chief Medical Officer	C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall	10 percent owner	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly	director	ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy	officer: Chief Medical Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo	officer: Sr. Vice President, Research	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014